Article

Eye and cornea research made easier by two antibodies

A global biotechnology company focused in inflammation and neurology research, announced the launch of two monoclonal antibodies (Lumican and Keratocan, MD Biosciences).

St. Paul, MN-A global biotechnology company focused in inflammation and neurology research, announced the launch of two monoclonal antibodies (Lumican and Keratocan, MD Biosciences). Both antibodies play a role in the development and maintenance of corneal transparency making them ideal for applications in eye and cornea research.

The antibodies belong to the Small Leucine Rich Proteglycan family. Keratocan originally was found to be a cornea-specific keratan sulphate proteoglycan. Lumican is a proteoglycan expressed in extracellular matrix and connective tissues where it has been reported to contribute to collagen fibrillogenesis, tissue hydration, migration, and proliferation.

Lumican modified with keratan sulphate, constitutes one of the major proteoglycans of the corneal stroma, where it stimulates cell migration on the corneal epithelium and also is believed to play a regulatory role for keratocan.

The Lumican antibody recognizes a protein epitope and is specific for human, bovine, mouse, and porcine tissues. The keratocan antibody recognizes a protein core epitope and is specific for human, bovine, porcine, mouse, and chicken tissues.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) CCOI's new CEO Malvina Eydelman, MD, outlines her mission and vision for the organization
CIME 2025: Neda Shamie, MD, on expanding options in pharmacological presbyopia management
© 2025 MJH Life Sciences

All rights reserved.